Total Funding
73
58
Total FundingSeries D raised
Growth Score
-16 pts
Heat Score
-27 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10725
Spyglass Pharma provides medicine for ophthalmic diseases.
- Glenn Sussman: Co-Founder and CTOPast Role: Alcon, Director R&D
- Patrick Mooney: Chief Executive OfficerPast Role: Galderma, Senior Director of Commercial Development
About the Company
Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications.
